© ACCESS Newswire
23.05.2025
CLBX
LISTED
AIMX
Angle PLC Announces Notice of Results
News Preview
Notice of Preliminary Results and Webcast GUILDFORD, SURREY / ACCESS Newswire / May 23, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, will be releasing its preliminary results for the year...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
LEGN
LISTED
NASDAQ
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
News Preview
SOMERSET, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new data evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients living with multiple myeloma will be presented at the 2025 American Society of Clinical Oncology (ASCO)...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
GMAB
LISTED
CPH
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
News Preview
Media ReleaseCOPENHAGEN, Denmark; May 22, 2025...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
22.05.2025
RAY B
LISTED
STO
Bulletin from the Annual General Meeting 2025
News Preview
The Annual General Meeting 2025 of RaySearch Laboratories AB (publ) was held on May 22, 2025, in Stockholm, Sweden. The following resolutions were adopted.
STOCKHOLM, May 22, 2025 /PRNewswire/ -- It was resolved to re-elect Carl Filip Bergendal, Johan Löf, Günther Mårder, Britta Wallgren and Hans Wigzell as Board members of the company and to re...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
22.05.2025
GNFT
LISTED
EURONEXT
GENFIT Reports First Quarter 2025 Financial Information
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues for the first three...
Themefolio
Profiler
Peergroup
© ActuNews
22.05.2025
OXUR
LISTED
EURONEXT
Oxurion Announces Results on the Annual Shareholders' Meeting of 13 May 2025
News Preview
Leuven, BELGIUM – May 22, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders' meeting on May 13, 2025. The shareholders approved all items on the agenda of the annual shareholders' meeting.
All documents pertaining to the annual shareholde...
Themefolio
Profiler
Peergroup
© ActuNews
22.05.2025
OXUR
LISTED
EURONEXT
Oxurion kondigt resultaten aan van de Jaarlijkse Aandeelhoudersvergadering van 13 mei 2025
News Preview
Leuven, BELGIË – 22 mei 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft zijn jaarlijkse aandeelhoudersvergadering gehouden op 13 mei 2025. De aandeelhouders keurden alle punten op de agenda van de jaarlijkse aandeelhoudersvergadering goed.
Alle docume...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
HELP
LISTED
NASDAQ
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a Water T...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
POAI
LISTED
NASDAQ
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
News Preview
Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Participate in Upcoming Investment Conferences
News Preview
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
TIL
LISTED
NASDAQ
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated i
News Preview
Phase 3 trial of ‘2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
22.05.2025
ORNBV
LISTED
HEL
Orion to host Capital Markets Day today, 22 May 2025, in Helsinki
News Preview
ORION CORPORATION INVESTOR NEWS 22 MAY 2025 at 10.15 EEST ...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
IBAB
LISTED
EURONEXT
IBA Business Update Q1 2025
News Preview
Year starting on track...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies
News Preview
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies...
Themefolio
Profiler
Peergroup
© BusinessWire
21.05.2025
TEM
LISTED
NASDAQ
Tempus to Present at the William Blair 45th Annual Growth Stock Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference. The event will take place from June 3-5 in Chicago, IL.
Jim Rogers, Chief Financial Officer of Tempus, will present on June 5. A live audio webcas...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
GMAB
LISTED
CPH
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference
News Preview
Media ReleaseCOPENHAGEN, Denmark; May 21, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferies Global Health Care Conference in New York City, New York at 9:20 EDT (3:20 PM CEST) on June 5, 2025. A webcast of the fireside chat will be available on...
Themefolio
Profiler
Peergroup
© EQS Newswire
21.05.2025
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva SE | Rating: Buy
News Preview
Original-Research: Valneva SE - from First Berlin Equity Research GmbH
21.05.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain......
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
CELC
LISTED
NASDAQ
Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
News Preview
MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following invest...
Themefolio
Profiler
Peergroup
© PR Newswire
21.05.2025
SECT_B
LISTED
STO
Invitation to presentation of Sectra's year-end report 2024/2025
News Preview
LINKÖPING, Sweden, May 21, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) invites investors, analysts, and the media to a presentation of the company's year-end report with President Torbjörn Kronander and CFO Jessica Holmquist.
Publication of the financial report: 8:15 a.m. (CEST) on June 5,...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
IBAB
LISTED
EURONEXT
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan
News Preview
The Cyclone® IKON is IBA’s high energy and high-capacity cyclotron which offers the largest energy spectrum for the production of PET and SPECT isotopes from 13 MeV to 30 MeV...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
ORNBV
LISTED
HEL
Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers
News Preview
ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST ...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
EHAB
LISTED
NYSE
Enhabit Announces Participation in Goldman Sachs 46th Annual Global Healthcare Conference
News Preview
Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference.
Enhabit’s President and CEO Barb Jacobsmeyer and Chief Financial Officer Ryan Solomon will participate in a fireside chat on Tuesday, June 10, at 10 a.m. EDT. The firesid...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2025
GNFT
LISTED
EURONEXT
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen’s Iqirvo®1 has been granted pricing and reimbursement in Italy for Prima...
Themefolio
Profiler
Peergroup
© ActuNews
20.05.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – May 20, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on May 16, 2025, from Atlas Spe...
Themefolio
Profiler
Peergroup
© ActuNews
20.05.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 20 mei 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transparant...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2025
GMAB
LISTED
CPH
Capital Increase in Genmab as a Result of Employee Warrant Exercise
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© PR Newswire
20.05.2025
CU6
LISTED
ASX
Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
News Preview
SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has commenced its second registrational Phase III 64Cu-SAR-bisPSM...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
TEM
LISTED
NASDAQ
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
HELP
LISTED
NASDAQ
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, applauds recent comments made by Dr. Martin Makary, Commissioner of the U.S. FDA relating to the importan...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
News Preview
- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
ICLR
LISTED
NASDAQ
ICON releases its ICON Cares 2024 Report
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is delivering on its environmental, social and governance (ESG) goals, as delivered through its ICON Cares program.
In recognition of its efforts in 2024, ICON r...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
DFTX
LISTED
NASDAQ
MindMed Announces New Employee Inducement Grants
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 53,350 common...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
IBAB
LISTED
EURONEXT
IBA – ACQUISITION OF OWN SHARES
News Preview
...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.05.2025
FYB
LISTED
XETR
Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
News Preview
Press Release // May 19, 2025
Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce today that the U.S. Food and Drug Administration (FDA) designated F......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.05.2025
FYB
LISTED
XETR
Formycon und Fresenius Kabi geben FDA-Zulassung von FYB202/Otulfi® (Ustekinumab-aauz) als austauschbares Biosimilar („interchangeable“) bekannt
News Preview
Pressemitteilung // 19. Mai 2025
Formycon und Fresenius Kabi geben FDA-Zulassung von FYB202/Otulfi® (Ustekinumab-aauz) als austauschbares Biosimilar („interchangeable“) bekannt
Planegg-Martinsried - Die Formycon AG (FWB: FYB, Prime Standard, „Formycon“) und ihr Kommerzialisierungspartner Fresenius Kabi geben heute bekannt, dass die US-amerikani......
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
GMAB
LISTED
CPH
Transactions in Connection with Share Buy-back Program
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
ZLAB
LISTED
NASDAQ
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the Company’s potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC), for the treatment of extensive-stage small cell lung cancer (ES-SCLC). ZL-1310, which is being evaluated...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
NSIS B
LISTED
CPH
Combining EVP roles of Human Health Biosolutions and Strategy & Integration
News Preview
As a next step on Novonesis’ integration journey, we combine the two EVP areas Human Health Biosolutions and Strategy & Integration. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
SKYE
LISTED
NASDAQ
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
News Preview
Proprietary formulation technology being applied to potentially enhance properties of nimacimab Proprietary formulation technology being applied to potentially enhance properties of nimacimab...
Themefolio
Profiler
Peergroup
© BusinessWire
16.05.2025
BLUE
LISTED
NASDAQ
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
News Preview
As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. The parties have issued the following updated...
Themefolio
Profiler
Peergroup
© ActuNews
16.05.2025
OXUR
LISTED
EURONEXT
Oxurion annonce la signature de l'accord ferme d'acquisition du français Axiodis CRO, spécialiste français de la biométrie
News Preview
Louvain, Belgique, le 16 mai 2025 à 8h30, Oxurion NV (Euronext Bruxelles : OXUR), société biopharmaceutique engagée dans le développement de thérapies innovantes, annonce la signature de l'accord ferme d'acquisition, via sa filiale française à 100% Oxurion France, de 72?% du capit...
Themefolio
Profiler
Peergroup
© ActuNews
16.05.2025
OXUR
LISTED
EURONEXT
Oxurion announces the signing of a binding agreement to acquire French biometrics specialist Axiodis CRO
News Preview
Louvain, BELGIUM – May 16, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company focused on the development of innovative therapies, announces the signing of a binding agreement to acquire 72% of the share capital of Axiodis CRO through its wholly owned French subsidiary, Oxurion France. The transaction amount...
Themefolio
Profiler
Peergroup
© ActuNews
16.05.2025
OXUR
LISTED
EURONEXT
Oxurion kondigt de ondertekening aan van een bindende overeenkomst tot overname van de Franse biometriespecialist Axiodis CRO
News Preview
Leuven, BELGIË – 16 mei 2025 om 8:30 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf dat zich toelegt op de ontwikkeling van innovatieve therapieën, kondigt de ondertekening aan van een bindende overeenkomst voor de overname van 72% van het aandelenkapitaal van Axiodis CRO via zijn volledig in Frankrijk...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2025
REC
LISTED
EURONEXT
RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM
News Preview
ISTURISA® (osilodrostat) is a cortisol synthesis inhibitor that blocks the enzyme 11beta-hydroxylase to help normalize hypercortisolemia in Cushing's syndrome, a rare endocrine condition that can have significant impact on patients and their familiesThe expanded indication is supported by an extensive clinical development programMILAN and BRIDGEW...
Themefolio
Profiler
Peergroup
© ActuNews
15.05.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – May 15, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on May 15, 2025, from Atlas Spe...
Themefolio
Profiler
Peergroup
© ActuNews
15.05.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 15 mei 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transparant...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2025
KDEV
LISTED
STO
Karolinska Development’s Annual General Meeting 2025
News Preview
STOCKHOLM, SWEDEN – May 15, 2025. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 15, 2025. The shareholders have had the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the articles of association. Therefore, shareholders have had the...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
LIVN
LISTED
NASDAQ
LivaNova to Present at the Jefferies Global Healthcare Conference
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time.
The discussion will be available to all i...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
SLP
LISTED
NASDAQ
Simulations Plus Releases DILIsym® 11
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platfo...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
HELP
LISTED
NASDAQ
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has engaged Thermo Fisher Scientific (“Thermo Fisher”), the world leader in servi...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2025
AMRX
LISTED
NASDAQ
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
News Preview
BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya® (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRA...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2025
TRAW
LISTED
NASDAQ
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
News Preview
FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule”...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2025
POAI
LISTED
NASDAQ
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2025
BIOA B
LISTED
STO
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)
News Preview
STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 (April 2025 through March 2026), corresponding to a 73 percent growth compared to the previous year. This w...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2025
BIOA B
LISTED
STO
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)
News Preview
STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 (April 2025 through March 2026), corresponding to a 73 percent growth compared to the previous year. This w...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2025
SECT_B
LISTED
STO
Guelph General Hospital adds digital pathology to cloud service from Sectra--enables integrated diagnostics for improved patient care
News Preview
LINKÖPING, Sweden and MISSISSAUGA, ON, May 15, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that Guelph General Hospital in Canada will be the first in the country to add Sectra's digital pathology module to its current cloud service, Sectra One Cloud. This addition will provide pa...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2025
1SXP
LISTED
XETR
SCHOTT Pharma delivers strong second quarter of fiscal year 2025
News Preview
SCHOTT Pharma delivers strong second quarter of fiscal year 2025
Q2 2025 revenues up 8% yoy to EUR 252m; increase of 10% yoy at constant currencies
Q2 2025 EBITDA margin of 28.6% as reported and 28.2% at constant currencies
Share of strong-margin high-value solutions (HVS) at 56% in Q2 2025
SCHOTT Pharma reaffirms FY 2025 guidance
SCHOTT Pharma......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
